期刊
AGEING RESEARCH REVIEWS
卷 49, 期 -, 页码 125-143出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.arr.2018.10.008
关键词
Aging-associated diseases; Alzheimer's disease; Cancer; microRNA; Biomarkers; Blood-based diagnostics
资金
- European Union [665735, 737390]
- Polish Ministry of Science and Higher Education [3548/H2020/COFUND/2016/2]
- Foundation for Polish Science (FNP)
- European Union -The European Regional Development Fund within the Operational Programme Innovative economy
- Marie Curie Actions (MSCA) [665735] Funding Source: Marie Curie Actions (MSCA)
microRNAs (miRNAs) have been extensively studied as potential biomarkers for Alzheimer's disease (AD). Their profiles have been analyzed in blood, cerebrospinal fluid (CSF) and brain tissue. However, due to the high variability between the reported data, stemming from the lack of methodological standardization and the heterogeneity of AD, the most promising miRNA biomarker candidates have not been selected. Our literature review shows that out of 137 miRNAs found to be altered in AD blood, 36 have been replicated in at least one independent study, and out of 166 miRNAs reported as differential in AD CSF, 13 have been repeatedly found. Only 3 miRNAs have been consistently reported as altered in three analyzed specimens: blood, CSF and the brain (hsa-miR-146a, hsa-miR-125b, hsa-miR-135a). Nonetheless, all 36 repeatedly differential miRNAs in AD blood are promising as components of the diagnostic panel. Given their predicted functions, such miRNA panel may report multiple pathways contributing to AD pathology, enabling the design of personalized therapies. In addition, the analysis revealed that the miRNAs dysregulated in AD overlap highly with miRNAs implicated in cancer. However, the directions of the miRNA changes are usually opposite in cancer and AD, indicative of an epigenetic trade-off between the two diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据